JP2015505557A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505557A5
JP2015505557A5 JP2014555561A JP2014555561A JP2015505557A5 JP 2015505557 A5 JP2015505557 A5 JP 2015505557A5 JP 2014555561 A JP2014555561 A JP 2014555561A JP 2014555561 A JP2014555561 A JP 2014555561A JP 2015505557 A5 JP2015505557 A5 JP 2015505557A5
Authority
JP
Japan
Prior art keywords
item
subject
cancer
composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014555561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/021402 external-priority patent/WO2013115966A1/en
Publication of JP2015505557A publication Critical patent/JP2015505557A/ja
Publication of JP2015505557A5 publication Critical patent/JP2015505557A5/ja
Pending legal-status Critical Current

Links

JP2014555561A 2012-01-31 2013-01-14 治療的送達のためのシクロデキストリンに基づく重合体 Pending JP2015505557A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593108P 2012-01-31 2012-01-31
US61/593,108 2012-01-31
PCT/US2013/021402 WO2013115966A1 (en) 2012-01-31 2013-01-14 Cyclodextrin-based polymers for therapeutic delivery

Publications (2)

Publication Number Publication Date
JP2015505557A JP2015505557A (ja) 2015-02-23
JP2015505557A5 true JP2015505557A5 (cg-RX-API-DMAC7.html) 2016-03-03

Family

ID=48870740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555561A Pending JP2015505557A (ja) 2012-01-31 2013-01-14 治療的送達のためのシクロデキストリンに基づく重合体

Country Status (6)

Country Link
US (2) US20130196946A1 (cg-RX-API-DMAC7.html)
EP (1) EP2812008A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015505557A (cg-RX-API-DMAC7.html)
CN (1) CN104203255A (cg-RX-API-DMAC7.html)
HK (1) HK1204962A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013115966A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017177055A1 (en) * 2016-04-08 2017-10-12 Liang Zhao Cyclodextrin-based polymers for therapeutic delivery
CN110283259B (zh) * 2019-07-03 2021-12-10 宁夏医科大学 一种解热镇痛布洛芬-β-环糊精第一面衍生物及其制备方法
US20220265776A1 (en) * 2019-07-09 2022-08-25 Genesis Pharma Sa Combination
KR20210014368A (ko) * 2019-07-30 2021-02-09 한국과학기술원 사이클로덱스트린 중합체를 유효성분으로 함유하는 동맥경화증 예방 또는 치료용 약학적 조성물
ES2990069B2 (es) * 2023-04-24 2025-06-04 Fundacion Univ San Antonio Ucam Combinacion sinergica para el tratamiento de cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7476894A (en) * 1993-07-29 1995-02-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
CA2410632A1 (en) * 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
BR112012012210B8 (pt) * 2009-11-23 2021-05-25 Cerulean Pharma Inc conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
CA2927832C (en) * 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use

Similar Documents

Publication Publication Date Title
TWI854573B (zh) 藥物組合物、其用途及癌症的治療方法
Brannon-Peppas et al. Nanoparticle and targeted systems for cancer therapy
RU2017104909A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
JP2019504100A5 (cg-RX-API-DMAC7.html)
CN101742910A (zh) 治疗脑癌的方法
JP2010520289A5 (cg-RX-API-DMAC7.html)
JP6410795B2 (ja) カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物
Paluri et al. Second-line treatment for metastatic pancreatic cancer
CN1674938A (zh) 用于治疗癌症的vegf受体酪氨酸激酶抑制剂的组合
KR20140143166A (ko) 조합 요법에 의한 프로카스파제 3 활성화
Schmitt et al. Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Groupe
JP2018536655A5 (cg-RX-API-DMAC7.html)
JP2022552841A (ja) ポリマー薬物送達コンジュゲートならびにそれを作製および使用する方法
CN1658880A (zh) 用于治疗癌症的联合疗法
JP2019504860A (ja) セジラニブの一定間欠投与を含む方法
CN112386701A (zh) 抑制pd-l1的表达的抗肿瘤联合用药物及其应用
Dutcher et al. 20th‐Century Advances in Drug Therapy in Oncology—Part II
JP6461088B2 (ja) 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物
Wells et al. Neurotoxicity of biologically targeted agents in pediatric cancer trials
Langenberg et al. Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis
RU2697551C2 (ru) Новые производные peg
WO2025083568A1 (en) Novel small-molecule protein kinase inhibitors for implications in cancer treatment
WO2025083564A1 (en) Novel small molecule degrader as a potential anticancer
WO2025083561A1 (en) Novel lead small molecule inhibitors on undruggable target towards anticancer activity
WO2025083570A1 (en) Novel small-molecule agents in overcoming tumor regression in cancers